Novartis Oncology provides a full range of patient support services through Novartis Patient Assistance Now Oncology (PANO). A complete list of Novartis Oncology medications and their related assistance programs is provided in the Table.
Novartis PANO
Novartis PANO offers insurance benefit verification, information about financial assistance options, patient support counselors, patient navigators, and dedicated case managers who will assist patients in identifying which Novartis Oncology patient support programs they are eligible to receive, including the Novartis Oncology Universal Co-pay Program, free trial programs, and the Novartis Patient Assistance Foundation. To enroll, your patient will complete their portion of the PANO Service Request Form (SRF) online; once their portion is complete, the prescribing physician can complete their portion of the SRF. Click here to learn more or to enroll your patient in PANO.
Novartis also offers drug-specific programs for several medications, including Kisqali Care, Kymriah Cares, and Rydapt NOW.
Novartis Oncology Universal Co-pay Program
Enrollment requirements for this program vary by drug. Patients may be eligible for this program if they:
Have private/commercial health insurance that covers the cost of the prescribed Novartis medicine
Do not participate in Medicare, Medicaid, TRICARE, Veterans Affairs, Department of Defense, or any other federal or state healthcare program
Are a resident of the United States or Puerto Rico.
Click here to learn more or to enroll your patient in the Universal Co-pay Assistance Program, or call 877-577-7756.
Novartis Patient Assistance Foundation
The Novartis Patient Assistance Foundation (NPAF) provides assistance to uninsured and underinsured patients. Not all Novartis Oncology medicines are currently supported by NPAF. Patients may be eligible if they:
Are experiencing financial hardship and/or have no third-party insurance coverage
Reside in the United States
Have an income that meets the financial eligibility requirements
Kisqali Care is a PANO program that can provide copay assistance, free trials of Kisqali, a patient starter kit, and other helpful information and resources. Patients can enroll in Kisqali Care online or by calling 800-282-7630.
Kymriah Cares
Kymriah Cares is a support program designed to help patients access Kymriah, including financial assistance, patient support programs, information about insurance coverage, and coordination of care support. To learn more, patients can call 844-459-6742.
Rydapt NOW
Rydapt NOW is a PANO program that can provide copay assistance, free trials of Rydapt, and other helpful information and resources. To learn more, patients can call 800-282-7630.
TABLE Novartis Oncology/Supportive Care Drugs
Drugs
Indications
Patient support programs
Drug
Afinitor (everolimus) tablets/Afinitor Disperz (everolimus tablets for oral suspension)
HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy, in combination with an aromatase inhibitor; postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy or after disease progression on endocrine therapy, in combination with fulvestrant
Patients aged ≤25 years with relapsed or refractory B-cell precursor acute lymphoblastic leukemia; adults with relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma
Treatment, in combination with fulvestrant, of postmenopausal women, and men, with HR-positive, HER2-negative, advanced or metastatic breast cancer and PIK3CA mutation, as detected by an FDA-approved test, that is progressing during or after an endocrine-based regimen
Newly diagnosed acute myeloid leukemia with FLT3 mutation, in combination with cytarabine and daunorubicin induction and cytarabine consolidation; aggressive systemic mastocytosis, systemic mastocytosis with hematologic neoplasm, or mast-cell leukemia
Treatment of adult patients with Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with 2 or more tyrosine kinase inhibitors; treatment of adult patients with Ph+ CML in CP with the T315I mutation
Metastatic NSCLC in patients whose tumors have a mutation that leads to mesenchymal-epithelial transition exon 14 skipping as detected by an FDA-approved test
Ph+ chronic myeloid leukemia (CML); adults and pediatric patients aged ≥1 years with newly diagnosed Ph+ CML; pediatric patients aged ≥1 years with Ph+ CML resistant or intolerant to previous tyrosine kinase inhibitor therapy
Afinitor (everolimus) tablets/Afinitor Disperz (everolimus tablets for oral suspension) Indications
Postmenopausal women with advanced HR-positive, HER2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole; adults with progressive neuroendocrine tumors of pancreatic origin and adults with progressive, well-differentiated, nonfunctional neuroendocrine tumors of gastrointestinal or lung origin that are unresectable, locally advanced, or metastatic; adults with advanced renal-cell carcinoma after failure of treatment with sunitinib or sorafenib; adults with renal angiomyolipoma and TSC not requiring immediate surgery
Gleevec (imatinib mesylate) Indications
Ph+ chronic myeloid leukemia (Ph+ CML) in chronic phase; Ph+ CML in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy; relapsed or refractory Ph+ acute lymphoblastic leukemia (Ph+ ALL); newly diagnosed Ph+ ALL in combination with chemotherapy; myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor receptor (PDGFR) gene rearrangements; aggressive systemic mastocytosis without the D816V c-Kit mutation or with c-Kit mutational status unknown; hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) in patients who have the FIP1L1-PDGFRα fusion kinase and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown; unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans; Kit (CD117)-positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST); adjuvant treatment of adult patients following resection of Kit (CD117)-positive GIST
Hycamtin (topotecan hydrochloride) for injection Indications
Metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy, as a single agent; small-cell lung cancer platinum-sensitive disease that progressed at least 60 days after initiation of first-line chemotherapy, as a single agent; stage IV-B, recurrent, or persistent cervical cancer that is not amenable to curative treatment, in combination with cisplatin
Mekinist (trametinib) Indications
Single agent in BRAF-inhibitor treatment-naive patients, or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test; in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection; in combination with dabrafenib, for the treatment of patients with metastatic NSCLC with BRAF V600E mutation as detected by an FDA-approved test; in combination with dabrafenib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer with BRAF V600E mutation and with no satisfactory locoregional treatment options
Tafinlar (dabrafenib) Indications
Single agent in BRAF-inhibitor treatment-naive patients, or in combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test; in combination with trametinib, for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection; in combination with trametinib, for the treatment of patients with metastatic NSCLC with BRAF V600E mutation as detected by an FDA-approved test; in combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer with BRAF V600E mutation and with no satisfactory locoregional treatment options
Tykerb (lapatinib) Indications
In combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy, including an anthracycline, a taxane, and trastuzumab; in combination with letrozole for the treatment of postmenopausal women with HR-positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated
Report Broken Links
Have you encountered a problem with a URL (link) on this page not loading correctly or is displaying an error message?
